Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-93.90%-.--% - - 50
+2.21%-1.15%-32.78%-17.09% 153B
+1.17%-1.38%-6.71%-8.33% 101B
-1.82%-2.14%+55.70%+57.60% 55.9B
+3.14%-0.83%-4.77%+48.74% 52.78B
+1.97%-1.65%-15.88%-44.35% 38.77B
+1.86%-4.13% - - 29.35B
+0.15%-4.78%-12.75%-45.04% 26.65B
+0.95%+0.90%+53.46%-9.39% 23.29B
-2.25%-1.17%-17.98%-3.98% 20.51B
Average -8.63%-2.36%+2.29%-2.73% 55.75B
Weighted average by Cap. +1.27%-1.78%-6.17%-1.88%
Logo Arbios Systems, Inc.
Arbios Systems, Inc. (Arbios) is a medical device and cell-therapy company focused on the development of products for the treatment of liver failure. The Company's lead product candidates under development consist of a extracorporeal blood purification therapy called the SEPET Liver Assist Device and an extracorporeal, bioartificial liver therapy referred to as the HepatAssist Cell-Based Liver Support System that incorporate porcine pig liver cells. In October 2008, Arbios announced that it has sold all its rights and interest in its bioartificial liver system, HepatAssist, to HepaLife Technologies, Inc. On January 9, 2009, Arbios announced that it filed for protection under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!